N

ENDRA Life Sciences
D

NDRA

5.99000
USD
0.23
(3.99%)
مغلق
حجم التداول
200
الربح لكل سهم
-717
العائد الربحي
-
P/E
-0
حجم السوق
3,216,079
أصول ذات صلة
    A
    ATHX
    0.00290
    (2.96%)
    0.10100 USD
    C
    CAPR
    0.100
    (0.54%)
    18.620 USD
    C
    CERS
    -0.07500
    (-4.18%)
    1.72000 USD
    D
    DRRX
    -0.12820
    (-11.45%)
    0.99180 USD
    I
    IMGN
    0
    (0%)
    0.000000 USD
    K
    KPTI
    -0.02960
    (-3.54%)
    0.80740 USD
    M
    MRKR
    -0.63000
    (-17.21%)
    3.03000 USD
    O
    OCUL
    -0.77000
    (-7.75%)
    9.16000 USD
    X
    XOMA
    0.590
    (1.98%)
    30.460 USD
    المزيد
الأخبار

العنوان: ENDRA Life Sciences Inc

القطاع: Healthcare
الصناعة: Diagnostics & Research
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH),chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.